Live Breaking News & Updates on Molecular Drivers|Page 1

Stay updated with breaking news from Molecular drivers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its. ....

United States , San Diego , Sikander Ailawadhi , Francesco Passamonti , Lisocabtagene Maraleucel , Guillaume Cartron , Ravi Vij , Maroof Hasan , Mark Kaplan , Rachid Baz , Hemophagocytic Lymphohistiocytosis , Danny Jeyaraju , Sheida Hayati , Susan Bal , Samit Hirawat , Franck Morschhauser , Bristol Myers Squibb , Lauren Peres , Sujit Sheth , Marc Hoffmann , Tracy Chow , Hansc Lee , Michael Wang , Esther Oliva , Leslie Andritsos , Michele Delforge ,

Improved Understanding of Genomics Drives Excitement in High-Grade Meningiomas

At present, there are no FDA-approved systemic therapies for patients with high-grade meningiomas. However, there has been an increase in research surrounding the disease over the past decade, which is improving the prospect a targeted agent may become for this population. ....

United States , Nader Sanai , Priscilla Kaliopi Brastianos , Harvard Medical School , World Health Organization , Hospital Cancer Center , Ivy Brain Tumor Center , National Cancer Institute , Barrow Neurological Institute , National Cancer Institute Cooperative Group , Ivy Center , Kaliopi Brastianos , Massachusetts General Hospital Cancer Center , World Health , Barrow Neurological , Treatments Move Closer , Fda Approved Systemic Therapies For Patients With High Grade Meningiomas , Molecular Drivers , Brain Cancer ,

Researchers ID potential new drug target in bladder cancer

Researchers ID potential new drug target in bladder cancer
Experimental drug that reduces protein production slows disease progression in lab studies
May 25, 2021
•
By Sabrina Richards
/ Fred Hutch News Service
Drs. Andrew Hsieh (left) and Sujata Jana (right) found that blocking protein synthesis slows bladder tumor development and progression in lab studies.
Image courtesy of Drs. Andrew Hsieh and Sujata Jana
Reining in protein production could have therapeutic effects on bladder tumors, according to new work published today in the journal JCI Insight.
“This is the first time that it’s been shown that protein synthesis is necessary for efficient bladder cancer development,” said Dr. Andrew Hsieh, a Fred Hutchinson Cancer Research Center bladder and prostate cancer researcher and oncologist. ....

Andrew Hsieh , Sujata Jana , University Of Washington , Fred Hutchinson Cancer Research Center , Bladder Cancer , Molecular Drivers , Protein Synthesis , Human Biology , Cancer Etiology Prevention Outcomes , ஆண்ட்ரூ ஶியெ , சுஜாதா ஜன , பல்கலைக்கழகம் ஆஃப் வாஷிங்டன் , ஃப்ரெட் ஹட்சின்சன் புற்றுநோய் ஆராய்ச்சி மையம் , சிறுநீர்ப்பை புற்றுநோய் , மூலக்கூறு இயக்கிகள் , ப்ரோடீந் தொகுப்பு , மனிதன் உயிரியல் ,

Mark Foundation announces 2021 Emerging Leader Awards

E-Mail
The Mark Foundation for Cancer Research (MFCR) has awarded seven grants to promising early-career investigators for projects aimed at addressing unmet needs in cancer research. The Emerging Leader Award program empowers scientists to take on innovative, high-risk/high-reward projects that have significant potential to improve outcomes for cancer patients.
The 2021 MFCR Emerging Leaders are pursuing important studies in areas of basic, translational, and clinical cancer research, including probing the function of cancer stem cells in brain cancer, discerning the unique molecular features of lung cancer in older patients, and identifying therapeutic combinations that will increase the effectiveness of immune checkpoint inhibitors across multiple types of cancer. ....

United States , Michele Cleary , Zhao Zhu , Ken Hsu , Paul Cohen , Effie Apostolou , Sabrina Spencer , Tuomas Tammela , University Of Colorado Boulder , Children Medical Center Research Institute , Damon Runyon Cancer Research Foundation , Mark Foundation For Cancer Research , Rockefeller University , University Of Virginia , Memorial Sloan Kettering Cancer Center , Mark Foundation , Cancer Research , Emerging Leader Award , Emerging Leaders , Leader Awards , Weill Cornell Medicine , Enhancer Hubs , Maintain Cancer Stem Cell , Organellar Oxidative Metabolism , Molecular Drivers , Obesity Associated Breast ,